Brief: Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals

14/06/2024 12:40

June 14 (Reuters) - Syndax Pharmaceuticals Inc  SNDX.O :
    * SYNDAX PRESENTS UPDATED POSITIVE DATA FROM BEAT AML AND
AUGMENT-102 PHASE 1/2 COMBINATION TRIALS OF REVUMENIB IN
PATIENTS WITH ACUTE LEUKEMIAS AT EHA 2024 CONGRESS
    * SYNDAX PHARMACEUTICALS INC: PLANS TO INITIATE A PIVOTAL
TRIAL
WITH THIS COMBINATION IN FRONT-LINE NEWLY DIAGNOSED PATIENTS BY
YEAR-END 2024
    * SYNDAX PHARMACEUTICALS INC: 96% CRC (23 OF 24 PTS)
OBSERVED IN
BEAT AML TRIAL
    * SYNDAX PHARMACEUTICALS INC: 52% CRC (14 OF 27 PTS)
OBSERVED IN
AUGMENT-102 TRIAL

Source text for Eikon:  ID:nPn6VW2G3a 
Further company coverage:  SNDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))